{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:57:05Z","timestamp":1790722625218,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01124-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T02:42:41Z","timestamp":1780022561000},"page":"862-874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-6555","authenticated-orcid":false,"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-0339","authenticated-orcid":false,"given":"Giuseppe","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-1359","authenticated-orcid":false,"given":"Iris S. H.","family":"Kloots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5635-919X","authenticated-orcid":false,"given":"Peter H. J.","family":"Slootbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0919-9864","authenticated-orcid":false,"given":"Matthew","family":"Labriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-8542","authenticated-orcid":false,"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-3095","authenticated-orcid":false,"given":"Amanda","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Patry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2877-2518","authenticated-orcid":false,"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4185-2475","authenticated-orcid":false,"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-0685","authenticated-orcid":false,"given":"Rafael","family":"Morales-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marmolejo Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-2627","authenticated-orcid":false,"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-4125","authenticated-orcid":false,"given":"Daniela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-2531","authenticated-orcid":false,"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-6284","authenticated-orcid":false,"given":"Sara","family":"Merler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-7755","authenticated-orcid":false,"given":"Mariella","family":"Sorar\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-4741","authenticated-orcid":false,"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro","family":"C. Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"\u00fcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Bolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Dur\u00e0n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego Cacho","family":"Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-911X","authenticated-orcid":false,"given":"Nieves","family":"Mart\u00ednez Chanz\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-9223","authenticated-orcid":false,"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"T\u00fcrkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Bengisu","family":"Soyk\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-9885","authenticated-orcid":false,"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-714X","authenticated-orcid":false,"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tortola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-3697","authenticated-orcid":false,"given":"Ricardo","family":"Pereira Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8226","authenticated-orcid":false,"given":"Martino","family":"Pedrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1124_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"1124_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"1124_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149\u201358.","journal-title":"Lancet Oncol"},{"key":"1124_CR4","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"1124_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163\u201377.","journal-title":"Lancet"},{"key":"1124_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"1124_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"1124_CR8","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"1124_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"1124_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"1124_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"1124_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"key":"1124_CR13","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024:Jco2401798."},{"key":"1124_CR14","first-page":"1475","volume":"31","author":"E Bournakis","year":"2011","unstructured":"Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, et al. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011;31:1475\u201382.","journal-title":"Anticancer Res"},{"key":"1124_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.21873\/anticanres.13253","volume":"39","author":"H Miyake","year":"2019","unstructured":"Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, et al. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. Anticancer Res. 2019;39:1391\u20136.","journal-title":"Anticancer Res"},{"key":"1124_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659135","volume":"11","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Preisser F, Hoeh B, Schroeder M, W\u00fcrnschimmel C, Steuber T, et al. Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies. Front Oncol. 2021;11:659135.","journal-title":"Front Oncol"},{"key":"1124_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10147-024-02649-2","volume":"30","author":"T Uchimoto","year":"2025","unstructured":"Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, et al. Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium. Int J Clin Oncol. 2025;30:123\u201333.","journal-title":"Int J Clin Oncol"},{"key":"1124_CR18","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","volume":"22","author":"AM Aparicio","year":"2016","unstructured":"Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res. 2016;22:1520\u201330.","journal-title":"Clin Cancer Res"},{"key":"1124_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.urolonc.2014.01.004","volume":"32","author":"CG Rusthoven","year":"2014","unstructured":"Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol Oncol. 2014;32:707\u201313.","journal-title":"Urol Oncol"},{"key":"1124_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W, Shaw GK, Valen\u00e7a L, Bernard B, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018;78:889\u201395.","journal-title":"Prostate"},{"key":"1124_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41391-023-00764-1","volume":"27","author":"IM Shui","year":"2024","unstructured":"Shui IM, Burcu M, Shao C, Chen C, Liao CY, Jiang S, et al. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases. Prostate Cancer Prostatic Dis. 2024;27:728\u201335.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1124_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","volume":"76","author":"AA Hamid","year":"2019","unstructured":"Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, et al. Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer. Eur Urol. 2019;76:89\u201397.","journal-title":"Eur Urol"},{"key":"1124_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","volume":"7","author":"M Pedrani","year":"2024","unstructured":"Pedrani M, Salfi G, Merler S, Testi I, Cani M, Turco F, et al. Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2024;7:1199\u2013215.","journal-title":"Eur Urol Oncol"},{"key":"1124_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"N Matsubara","year":"2020","unstructured":"Matsubara N, Chi KN, \u00d6zg\u00fcro\u011flu M, Rodriguez-Antolin A, Feyerabend S, Fein L, et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. Eur Urol. 2020;77:494\u2013500.","journal-title":"Eur Urol"},{"key":"1124_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","volume":"34","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, et al. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. Ann Oncol. 2023;34:477\u201385.","journal-title":"Ann Oncol"},{"key":"1124_CR26","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","volume":"42","author":"RAM Laughlin","year":"2024","unstructured":"Laughlin RAM, Thomas H, Davis ID, Zielinski RR, Thomson A, Tan TH, et al. Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). J Clin Oncol. 2024;42:5079.","journal-title":"J Clin Oncol"},{"key":"1124_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1200\/JCO.2025.43.5_suppl.167","volume":"43","author":"A Tripathi","year":"2025","unstructured":"Tripathi A, Chen Y-H, Jarrard DF, Garcia JA, Dreicer R, Liu G, et al. Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: Final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial. J Clin Oncol. 2025;43:167.","journal-title":"J Clin Oncol"},{"key":"1124_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1124_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020;78:347\u201357.","journal-title":"Eur Urol"},{"key":"1124_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"1124_CR31","doi-asserted-by":"crossref","unstructured":"Raval AD, Lunacsek O, Korn MJ, Littleton N, Constantinovici N, George DJ. Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023. JCO Oncol Pract. 2025:Op2400690.","DOI":"10.1200\/OP-24-00690"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01124-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01124-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:19Z","timestamp":1790719219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01124-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01124-5","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FT reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Silvio Grasso Consulting (institutional), SAKK (institutional), Merck (institutional), Novartis (istitutional), Bayer (individual) and MSD (individual); support for attending meetings or travel from Bayer (individual); and participation on a data safety monitoring board or advisory board for Bayer (individual) and Telix (individual). SG (last 2 years) personal honoraria for invited speaker for Schweizerische Gesellschaft f\u00fcr Medizinische Onkologie (SGMO)\/Meister ConCept GmbH; other honoraria from University of Applied Sciences and Arts of Southern Switzerland (SUPSI). Travel grants from Bayer, Gilead, Intellisphere LLC, Johnson & Johnson. Institutional honoraria advisory boards or in Independent Data Monitoring-\/Steering Committees from Amgen, Astellas, AstraZeneca, Avalere Health, Bayer, Bristol-Myers Squibb, GSK, Ipsen, LinkinVax, Macrogenics, Merck, MDS Merck Sharp & Dohme, Novartis, Pfizer; invited speaker for Emirates Oncology, EPG Health, ESMO, Intellisphere LLC, Medtoday Switzerland, Orikata, PeerVoice, Pfizer, Schweizerische Gesellschaft f\u00fcr Medizinische Onkologie (SGMO)\/Meister ConCept GmbH, Silvio Grasso Consulting, Swiss group for Clinical Cancer Research (SAKK)\/Swiss Cancer Institute (SCI), SwissInfoMed, Symposia Congressi, UroPratica Group. Patent for a research method for biomarker WO2009138392. KF reports honoraria for lectures from AstraZeneca, Bayer, Ono, Eisai, MSD, Bristol-Myers Squibb, Takeda, Merk, Astellas, Janssen, and Novartis. HS reports research funding from Astellas, AstraZeneca, Bayer, Chugai, Eli-lily, Janssen, MSD, Nihon Kayaku, and Sanofi; advisory fees from Astra Zeneca, Bayer, Chugai-Roche, Eli Lilly, Ferring, Janssen, MSD, Novartis, Pfizer, and Sanofi; and lecture fees from Astellas, AstraZeneca, Bayer, Janssen, Novartis, Pfizer, and Sanofi. CNS reports Consulting fees: Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb\/Medarex; Gilead; Merck; MSD; Pfizer; Janssen; Roche; Medscape; UroToday; Tolmar; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Merck; Pfizer GP reports financial Interests: ACCORD Healthcare Italia Srl, Steeering Committee, Personal, consultant fees; Astellas, Advisory Board, Personal, consultant fees; Astrazeneca, Advisory Board, Personal, consultant fees; Amgen, Advisory Board, Personal, consultant fees; Boehringer, Advisory Board, Personal, consultant fees; Bayer, Advisory Board, Personal, consultant fees; Brystol Myers Squibb, Advisory Board, Personal, consultant fees; Ipsen, Advisory Board, Personal, consultant fees; Janssen, Advisory Board, Personal, consultant fees; Eisai, Advisory Board, Personal, consultant fees; Janssen Cilag, Advisory Board, Personal, consultant fees; Merck Sharp & Dohmes, Advisory Board, Personal, consultant fees; Merck, Advisory Board, Personal, consultant fees; Pfizer, Advisory Board, Personal, consultant fees; Roche, Advisory Board, Personal, consultant fees; Eli Lilly, Advisory Board, Personal, consultant fees; Menarini Group, Other, Personal, workgroup; Telix Pharmaceuticals Limited, Advisory Board, Personal, consultant fees; GE Medical Systems Italia SPA, Other, Personal, consultant fees; Ipsen, Research Grant, Institutional, research funding for no profit clinical trial Coordinating PI; Gilead, Research Grant, Institutional, research funding for no profit clinical trial; MSD, Research Grant, Institutional, research funding for no profit clinical trial; Janssen, Research Grant, Institutional, research funding for no profit clinical trial; Board of Directors : ASCO Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer living guideline 2025 MS reports travel support from 2022 Janssen; 2023: Novartis; 2024: Astellas, Ipsen; 2025: Bayer, Novartis DES reports personal Fees: AstraZeneca, Bayer, Boston Scientific, Janssen, Novartis, Pfizer PCB reports grants or personal fees from Astellas; AstraZeneca; Bayer, Eisai; Ipsen; Caris Life Sciences; Exelixis; Janssen, Pfizer, Sanofi, Seattle Genetics, BMS, Bayer, Guardant Health; Caris Life Sciences; Myovant; Medscape; UroToday; MJH Life Sciences CM received fee as speaker in symposia organized by J&j, Astellas, msd, Orion Pharma JDCL reports sonsultant advisory Role: Astrazeneca, BMS; speaking: Astrazneca, BMS, Leopharma, Rovi MCN reports research travel from Pfizer and Ipsen, consulting fees (institutional) from BMS, Bayer, Ipsen and Merck. LGH reports grants or contracts from any entity: astellas (institutional), Bayer (institutional); Consulting fees: Astellas (institutional), Bayer (institutional), Janssen (institutional); Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Astellas (institutional), Bayer (institutional), Janssen (institutional), Amgen (institutional); support for attending meetings and\/or travel: Bayer (institutional); patents planned, issued or pending: Australian Patent Application No. 2022902527 International (PCT) Patent Application No. PCT\/AU2023\/050849 Pending (institutional); Leadership or fiduciary role in other board, society, committee or advocacy group: ANZUP Board (unpaid) RM reports consulting fees: Bayer (individual); Support for attending meetings and\/or travel (individual) RC reports advisory role (institutional): MSD, Astra Zeneca, BMS, Merck, Roche, Bayer, Astellas, Janssen, Pfizer, Ipsen, Debiopharm, Accord, Novartis, Sandoz; Speaker role (institutional): Astellas, Janssen, Merck, Ipsen, Accord; Travel support (institutional): Ipsen, Astra Zeneca GLB reports personal fees from advisory boards (Accord, AstraZeneca, Amgen, Merck) and speaker bureaus (Astellas, AstraZeneca, Amgen, Bayer, Merck, Pfizer). Travel\/accommodation for scientific conferences: Accord, Merck, Janssen VC has served as a consultant\/advisory board member for Johnson&Johnson, Astellas, Merck, AstraZeneca, Amgen, EISAI, Recordati, Novartis, Ipsen, and Bayer and has received speaker honoraria or travel support from Astellas, Johnson&Johnson, Ipsen, Bayer, Gilead, Novartis, GSK and BristolMyers Squibb. HML reports employment with the Garvan Institute of Medical Research, and is a co-inventor of a patent for a prognostic biomarker in prostate cancer (PCT\/AU2023\/050849). The other authors declared no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}